Takhzyro was originally developed by the rare disease specialist Shire before it merged with Takeda at the beginning of this year in a deal worth around $62 billion.

The results compare well with plasma kallikrein inhibitor Takhzyro (lanadelumab) in HAE, which is given by subcutaneous injection every two weeks, but can be reduced to once a month if patients ...